Օմակոր

main_info

  • trade_name:
  • Օմակոր
  • dosage:
  • 1000մգ(28) պլաստիկե տարայում
  • pharmaceutical_form:
  • դեղապատիճներ փափուկ
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Օմակոր
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

30-11-2018

FDA authorizes first test to aid in detecting a type of herpes virus in newborns called cytomegalovirus

FDA authorizes first test to aid in detecting a type of herpes virus in newborns called cytomegalovirus

FDA authorizes first test to aid in detecting a type of herpes virus in newborns called cytomegalovirus

FDA - U.S. Food and Drug Administration

29-5-2018

Orphan designation:  Pasireotide,  for the: Treatment of acromegaly

Orphan designation: Pasireotide, for the: Treatment of acromegaly

Europe - EMA - European Medicines Agency

29-3-2019


EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack

EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack

EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack

Europe - EMA - European Medicines Agency

1-3-2019


First treatment for rare disease characterised by high levels of triglycerides in blood

First treatment for rare disease characterised by high levels of triglycerides in blood

First treatment for rare disease characterised by high levels of triglycerides in blood

Europe - EMA - European Medicines Agency

27-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes (ASP0113), decision type: , therapeutic area: , PIP number: P/0338/2014

Opinion/decision on a Paediatric investigation plan (PIP): Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes (ASP0113), decision type: , therapeutic area: , PIP number: P/0338/2014

Opinion/decision on a Paediatric investigation plan (PIP): Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes (ASP0113), decision type: , therapeutic area: , PIP number: P/0338/2014

Europe - EMA - European Medicines Agency

21-2-2019


Orphan designation: Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes, Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity deemed at..., 09/08/2012, Withdrawn

Orphan designation: Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes, Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity deemed at..., 09/08/2012, Withdrawn

Orphan designation: Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes, Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity deemed at..., 09/08/2012, Withdrawn

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Europe - EMA - European Medicines Agency

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Europe - EMA - European Medicines Agency